Drug Profile
Imiglitazar
Alternative Names: TAK 559Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Takeda
- Class Antihyperglycaemics
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 30 Mar 2005 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (unspecified route)
- 30 Mar 2005 Discontinued - Phase-III for Type-2 diabetes mellitus in Europe (unspecified route)
- 30 Mar 2005 Discontinued - Phase-III for Type-2 diabetes mellitus in USA (unspecified route)